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Abstract
Background: Squamous cellular carcinoma antigen (SCCA) is overexpressed in hepatocellular carcinoma (HCC)
tissue and in sera of HCC patients. Our aim was to assess hepatic SCCA immunostaining in a series of HCCs and to
correlate its presence with cell proliferation, apoptosis and clinical outcome.
Methods: Sixty-one HCC patients were included. Liver specimens were obtained either by biopsy (n = 17) or
surgically (resection 27, transplantation 17). Immunostaining for AFP, Ki-67, SCCA and TUNEL assay were performed.
Results: SCCA staining was detected in 83.6% of specimens. A statistical significant correlation was found between
negative SCCA staining and mortality (p = 0.026) and a higher immunostaining score for Ki67 (p = 0.017). Positive
SCCA staining was associated with well and moderate differentiated tumors (p = 0.022). Using multiple logistic
regression analysis, Ki67 and TUNEL assay were found to be significant independent predictors of negative SCCA
immunostaining. The area under the receiver operator characteristic curve was 0.87. Kaplan-Meier survival analysis
revealed a significant difference between the patient group with positive versus negative SCCA immunostaining
relating to survival time (p = 0.0106). Cox proportional hazard regression analysis demonstrated that Ki67
immunostaining and liver transplantation or resection were independently associated with mortality.
Conclusions: SCCA is overexpressed in HCC. SCCA status is associated with cell proliferation, apoptosis and
survival. SCCA and Ki67 staining can predict survival. Our study results support a potential association of negative
SCCA expression with other markers of poor outcome in HCC. More studies are needed to clarify the role of SCCA
in HCC and expand the knowledge of the SCCA antigen in HCC patients.
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Background
Hepatocellular carcinoma (HCC) is a major health pro-
blem [1,2]. Its incidence is increasing [3] and it has
become the leading cause of death amongst cirrhotic
patients [4]. The predominant risk factors are chronic
hepatitis B and chronic hepatitis C [5]. Llovet et al
reported that 80% of HCC cases developed in a cirrhotic
liver. Cirrhosis is the strongest predisposing factor [6].
A number of serum markers have been proposed as a
method of detecting HCC. However, alpha fetoprotein
(AFP), des-c-carboxy-prothrombin (DGCP) and AFP-L3
fraction are not sufficiently accurate to predict its early
diagnosis [7].
Dysregulation of the balance between proliferation and
cell death represents a pro-tumorigenic principle in
human hepatocarcinogenesis. The Ki-67 protein is asso-
ciated with active cell proliferation and expressed in all
phases of the cell cycle, except G0, with the highest
expression seen in G2/M.
In a study of patients who had undergone resection
for HCC, higher levels of expression of Ki-67 in tumor
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grade [8] and early disease recurrence [9]. The balance
between death and survival is dysregulated in HCC
mainly due to overactivation of anti-apoptotic pathways
such as Bcl-XL, Mcl-1, c-IAP1, XIAP or survivin, which
are over-expressed in HCC cells [10].
Squamous cellular carcinoma antigen (SCCA) is a
member of the high molecular weight family of serine
protease inhibitors (serpins) [11]. High levels have been
reported in cancer of the head and neck tissue and
other epithelial cancers [12]. It has also been reported
to overexpress in HCC tissue and in serum from HCC
patients [13]. SCCA has been reported to overexpress in
tumoral compared to peritumoral tissue, suggesting a
role as a potential marker for histological detection of
HCC [14].
The aim of this study was to assess SCCA immunos-
taining in a series of HCCs of different etiologies and
characteristics and correlate its presence with cell prolif-
eration, apoptosis and survival.
Patients and Methods
Patients’ cohort
This study was simultaneously conducted in two large
transplant medical centers in Israel: Beilinson Hospital,
Rabin Medical Center, Petah Tiqwa (affiliated with the
Sackler School of Medicine, Tel Aviv University, Tel
Aviv) and Hadassah-Hebrew University Hospital, Jerusa-
lem. A search was performed in the pathology depart-
ments of both hospitals for patients diagnosed with
HCC. These patients were followed up at the Liver
Institute, Beilinson Hospital or the Liver Unit, Hadas-
sah-Hebrew University Hospital from January 2004
through December 2010, inclusive. Exclusion criteria
were either insufficient liver tissue on the biopsy speci-
men for extra analysis (9) or insufficient clinical data
regarding patient outcome (3). These last patients were
non-Israeli citizens and either had returned home to
their countries after obtaining a diagnosis or had been
treated. The survival period was calculated from the
point that tissue diagnosis was performed until either
the patient’s death or termination of follow up (April
2011) (whichever came first). Mortality data were
retrieved from the computer system of the Ministry of
Interior affairs via the hospital computers.
Serum AFP was measured in all cases. HCC diagno-
sis was confirmed by the presence of a focal lesion > 2
cm detected by liver ultrasound (US), computed tomo-
graphy and magnetic resonance imaging, when indi-
cated. Liver specimens, formalin-fixed and paraffin-
embedded, used to diagnose HCC were obtained
from all patients either by US-guided biopsies or surgi-
cally in patients who had undergone resection or
transplantation.
Serum AFP Level
Immunoassay was used to analyze serum sample AFP
levels (Roche Diagnostics) using the Modular Analytics
E170.
Histological Evaluation
The SCCA was analyzed by immunohistochemistry in
paraffin sections. A score was obtained by assessing
entire sections in each case and each nodule in cases of
multiple malignant nodules. The highest score was used.
For SCCA detection, a novel polyclonal rabbit antibody
(Hepa-Ab, Xeptagen, Italy), raised against recombinant
SCCA1 and affinity purified on a Sepharose-SCCA1 col-
umn, was used.
Epitope mapping studies with SCCA1 fragments
obtained by SCCA1 enzymatic digestion or chemical
synthesis indicated that the affinity-purified polyclonal
antibody recognized several epitopes located in the N-
terminal, C-terminal and the central portion of SCCA1
(determined by an enzyme-linked immunosorbent assay
(ELISA) and Western blot). The concentration level of
Hepa-Ab used was 4 mg/mL. Sections were incubated
with primary antibodies for 30 minutes after blocking
endogenous peroxidase activity with 3% hydrogen perox-
ide. The slides were heated in 10 mM sodium citrate in a
microwave oven, blocking nonspecific protein binding in
normal goat serum. Biotinylated goat anti-rabbit (Dako,
Copenhagen, Denmark) was then added for 30 minutes.
Samples were incubated with avidin-biotin-peroxidase
and stained with a mixture of 3,30- diamino-benzidine
tetrahydrochloride (Dako) and hydrogen peroxide. As a
negative control, sections were incubated, omitting a
primary antibody. In each case, a diluent or appropriate
nonimmune IgG was substituted. Antibody specificity
was confirmed using human skin specimens for SCCA
as positive controls.
The percentage of stained cells in each specimen was
scored on a scale of 0-3: 0 denoted negative staining; 1 -
positivity in 1-30% of hepatocytes; 2- positivity in 31-
50%; and 3- in > 50%. Distribution of immunoreactivity
was noted and classified as diffuse patterns, clustered or
scattered cells.
In all cases, SCCA semiquantitative immunoreactivity
was independently evaluated by two pathologist experts
in the field. Intra and interobserver differences were <
5%. Discordant cases were simultaneously re-evaluated
by the two.
In all immunohistochemical analyses, necrotic areas
and edges of tissue sections were not included in the
counting as to avoid possible false positivity.
AFP Immunohistochemistry Staining
Immunohistochemistry on paraffin embedded sections
with alpha feto protein antibody was performed using a
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States). Sections were pretreated with protease enzymes
and incubated with a Rabbit Anti-Human Alpha-1-
Fetoprotein antibody (A008 DAKO DK-2600 Glostrup
Denmark) in a concentration of 1:300 for 40 minutes.
Ki-67 Immunohistochemistry Staining
The primary antibody was a mouse monoclonal anti-
human Ki-67 antigen (a mindbomb homolog 1 clone).
Immunohistochemistry on paraffin embedded sections
with Ki-67 was performed using a fully automated sys-
tem (Ventana Benchmark, United States). Briefly, heat
retrieval was standard for 60 minutes. Sections were
incubated with Ki-67 (M7240, Dako) and diluted 1:100
in an antibody diluent (00-3118, Zymed, San Francisco,
CA).
Only distinct nuclear staining of carcinoma cells was
used for scoring via the light microscope, determined
semiquantitatively as nil (no immunostaining), low (10%
or less immunopositivity) or high (> 10% immunoreac-
tive cells), respectively. Assessment was carried out on
the entire tumor represented in the section.
Terminal Deoxynucleotidyl Transferase dUTP Nick End
Labeling (TUNEL) Assay
Apoptotic cell nuclei were identified by applying an
ApoTag in situ apoptosis peroxidase detection kit using
the TUNEL assay (Intergen Co., New York, NY). This
assay is designed to specifically detect the fragmented
DNA of apoptotic cells by catalytically incorporating
fluorescein-12-2’-deoxyuridine 5’-triphosphate at the 3’-
OH DNA ends using the terminal deoxynucleotidyl
transferase enzyme, thus forming a polymeric tail. The
fluorescein-12-2’-deoxyuridine 5’-triphosphate-labeled
DNA can subsequently be directly visualized by fluores-
cence microscopy. Hepatocytes with nuclear positivity
for DNA fragmentation were counted in 50 ± 5 fields
(original magnification ×10).
All practices conformed to institutional guidelines for
the protection of human subjects.
Statistical Analysis
Descriptive statistics are given as median, mean and
standard deviation (SD) for continuous variables and
frequency distribution for categorical variables. Logarith-
mic transformation was applied to the serum AFP vari-
able due to skewed distribution of the data. Chi-square
or Fisher’s exact test were used for categorical variables;
the two-sample t-test for continuous variables. A multi-
ple logistic regression model was applied to assess para-
meters independently associated with SCCA. A receiver
operator characteristic (ROC) curve was drawn and the
area under the curve (C parameter) was used to quantify
the predictive ability of the final regression model. The
Kaplan-Meier method was used to evaluate survival rate.
Differences in survival between groups were analyzed by
the Log-rank test. The Cox proportional hazards regres-
sion model was also applied. Results are presented as
hazard ratios (HR), together with their 95% confidence
intervals. Statistical analyses were performed using SAS
for Windows 9.2.
Results
Mean age of the 61 patients included in the study was
63.18 ± 10.60 years; 70.49% were male. Thirty (49.18%)
patients were anti-HCV positive, 17 (27.87%) HBsAg
p o s i t i v e ,4( 6 . 5 5 % )a d m i t t e da l c o h o la b u s e ,a n dt h e
remaining 9 (16.4%) had no identified risk factors. One
tumor lesion was found in 55.9% of the patients and > 1
in 44.1%. Mean tumor size was 5.25 ± 3.93 cm. Tumor
differentiation was well in 36.0% of patients, moderate
in 47.5% and poor in 8.2%. Treatment options included
resection (n = 27), liver transplantation (n = 17) and
chemoembolisation (n = 37).
SCCA Immunostaining
SCCA expression in HCC is shown in Figure 1. SCCA
was detected in 51 (83.6%) specimens; 17 (27.87%) from
transplant specimens; 27 (44.26%) from resection and 17
(27.87%) from fine-needle ultrasound guided biopsies;
undetected in 6 surgically obtained normal human
livers. A positive signal was clearly detectable in 50% of
the cases, with a scored of 1, 19.7% with a score of 2
and 20.3% with a score of 3, Table 1.
SCCA was detected in the cell cytoplasm with a pre-
valent diffuse pattern. In poorly differentiated tumors, a
typical clustered coarse pattern was observed (Figure 1).
A statistically significant correlation was found between
SCCA staining and: 1) mortality: negative SCCA staining
was associated with 100% mortality vs a 64.71% in posi-
tive SCCA staining (p = 0.026); 2) tumor differentiation:
positive SCCA staining was associated with well and
moderate differentiated tumors in 95.85% of specimens
(p = 0.022); 3) Ki67 immunostaining: negative SCCA
staining was associated with a higher Ki67 score (p =
0.017). However, no such correlation was detected in age,
sex, etiology of chronic liver disease, tumor diameter and
number, serum AFP, AFP and TUNEL staining (border-
line), type or level of SCCA staining (Table 2).
AFP Immunostaining
AFP staining was negative in 70.7% of the specimens.
No correlation was detected between AFP staining and
SCCA staining or any clinical parameter.
Ki67 Immunostaining
Mean Ki67 score was 0.3190 for negative SCCA staining
vs. 0.1086 for positive SCCA staining (p = 0.017).
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Mean TUNEL score was 0.411 ± 0.30 for negative
SCCA staining vs. 0.249 ± 0.25 for positive SCCA stain-
ing (p = 0.08).
Independent Predictors of Negative SCCA
Immunostaining
Ki67 and the TUNEL staining were significant indepen-
dent predictors of negative SCCA staining. Table 3
represents the multiple logistic regression analysis for
these variables.
ROC curve analysis (Figure 2) revealed that Ki67 and
TUNEL staining were excellent predictors for SCCA
staining. The C parameter was 0.87.
Kaplan-Meier Survival Analysis
A significant difference was noted between the two
patient groups (positive and negative SCCA staining) in
survival time (p = 0.0106) (Figure 3). The mean survival
time for negative SCCA staining patients was 19.13
months vs 39.78 months for positive staining patients.
Variables Independently Associated with Mortality
The following variables were found to be independently
associated with mortality: Ki67 staining, HBV, liver
transplantation and resection. Table 4 presents Cox pro-
portional hazard regression analysis for each parameter.
Discussion
Several studies have reported a high SCCA expression in
HCC tissues [13,14]. Giannelli et al [13] measured
serum SCCA in 120 HCC patients, 90 cirrhotics, and 41
healthy subjects. SCCA levels were significantly elevated
in HCC patients compared to cirrhotic or normal sub-
jects. The sensitivity and specificity for SCCA in HCC
diagnosis were 84% and 46%, respectively. Guido et al
[15] demonstrated aberrant expression of SCCA in HCC
and provided evidence that SCCA overexpression is an
early event in liver cell carcinomatous transformation
was consistently detected in all considered dysplastic
nodules.
The high SCCA expression in HCC tissue seems
remarkable since the liver does not possess squamous
Figure 1 Pattern of hepatic SCCA immunostaining in HCC.
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embryogenic origin. Further m o r e ,t h er o l eo fs e r p i n si n
neoplastic cells indicates that SCCA expression makes
cancer cells resistant to several killing mechanisms by
inhibition of apoptosis [16]. The SCCA antigen repre-
sents a marker for more advanced organ tumors such as
the cervix, lung and oropharynx [17]. A significant asso-
ciation was also noted between SCCA overexpression
and histological grade 2/3 HCC, suggesting SCCA as a
marker of cancer aggressiveness [15].
However, in our HCC patient cohort, positive SCCA
staining was associated with an improved survival rate.
We found that negative SCCA staining was associated
with a higher Ki67 score. In multiple logistic regression
analysis, the Ki67 and the TUNEL scores were signifi-
cant independent predictors of negative SCCA staining.
A previous study established that Ki-67 immunostaining
of HCC lesions was associated with higher mitotic activ-
ity [18]. D’Errico et al [9] demonstrated that higher
levels of Ki-67 expression in HCC tissue were associated
with a higher tumor grade. Nakanishi et al [8] noted
that higher levels of Ki-67 expression were associated
with early disease recurrence.
Insufficient apoptosis has been associated with the
development and progression of liver tumors. [10] In
HCC, the balance between death and survival is mainly
disrupted due to the overactivation of antiapoptotic sig-
nals. Therefore, liver cancer cells might express stronger
requirements of these intracellular pathways to survive.
Our study results are in accordance with Trerotoli et al
[19] who found that stronger staining was associated with
a smaller HCC. They speculated that the higher ratio in
smaller rather than larger hepatic nodules, suggests that
SCCA is produced and released at different times, likely
during the earlier events in HCC progression.
Table 1 Patients’ baseline characteristics (n = 61)
Variable
Mean age (years) 63.18 ± 10.60
Sex (M/F) (%) 70.5/29.5
Chronic HBV infection (%) 27.87
Chronic HCV infection (%) 49.18
Alcohol (%) 6.60
Other (%) 16.35
One lesion/multiple lesions (%) 55.93/44.07
Mean tumor size (cm) 5.25 ± 3.93
Mean serum AFP level (ng/mL) 4265.24 ± 10672.40
Tumor differentiation:
Well/moderate/poorly (%) 36/47.5/8.2
AFP immunostaining (positive/negative) (%) 29.27/70.73
Mean Ki67 score 14.42 ± 15.74
Mean TUNEL score 27.67 ± 26.99
SCCA immunostaining (positive/negative) (%) 83.6/16.4
SCCA scoring (%)
Score 1 50
Score 2 19.7
Score 3 20.3
Liver transplantation (%) 27.87
Hepatic resection (%) 44.26
Chemoembolization (%) 36.39 ± 33.66
Mean survival (months) 36.39 ± 33.66
Abbreviations: M/F = male/female; HBV = hepatitis B virus; HCV = hepatitis C
virus; AFP = alpha feto protein; TUNEL = Terminal Deoxynucleotidyl
Transferase dUTP Nick End Labeling; SCCA = squamous cellular carcinoma
antigen
Table 2 Comparison between 2 groups of HCC patients:
positive and negative SCCA immunostaining
Variable Positive SCAA Negative
SCCA
p
value
Age (years) 63.3 ± 10.8 62.4 ± 9.84 NS
HBV infection (positive, %) 27.45 30.00 NS
HCV infection (positive, %) 50.98 40.00 NS
Alcohol (positive, %) 5.88 10.00 NS
Other CLD (positive, %) 74.51 80.00 NS
Serum AFP level (ng/mL) 4853.41 ±
11432.3
736.24 ±
1072.51
0.027
Mean tumor size (cm) 5.13 ± 4.09 6.12 ± 2.71 NS
Tumor number (> 1, %) 84.62 87.88 NS
Tumor differentiation (%) 0.022
Well 37.25 30
Moderate 52.94 20
Poor 3.92 30
TUNEL score 0.24 ± 0.25 0.41 ± 0.30 0.08
Ki67 score 0.10 ± 0.11 0.319 ± 0.22 >
0.0001
AFP immunostaining
(negative, %)
60.0 70.7 NS
Liver transplantation (%) 31.37 10.0 NS
Hepatic resection (%) 60.0 54.9 NS
Chemoembolization (%) 60.0 52.94 NS
Survival (months) 39.78 ± 34.78 19.13 ± 20.88 0.026
Abbreviations: HBV = hepatitis B virus; HCV = hepatitis C virus; CLD = chronic
liver disease; AFP = alpha feto protein; TUNEL = Terminal Deoxynucleotidyl
Transferase dUTP Nick End Labeling
Table 3 Independent predictors of negative SCCA
staining
Effect Point Estimate 95% Wald p value
Confidence limits
Ki67 0.888 0.823 0.958 0.0022
TUNEL 0.957 0.921 0.995 0.0251
HBV 7.172 0.805 63.863 0.0774
Abbreviations: SCCA = squamous cellular carcinoma antigen; TUNEL =
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling; HBV =
hepatitis B virus
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Page 5 of 8Figure 2 ROC curve analysis for Ki67 and TUNEL immunostaining in predicting positive or negative SCCA immunostaining.
Figure 3 Kaplan-Meier analysis: A significant difference in survival time between positive and negative SCCA immunostaining groups.
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torical study. Due to the retrospective nature of our study,
variable treatment modalities of HCC were included. The
patients’ cohort was composed of only 61 patients. The
group size became even smaller when divided by the
SCCA positive and negative staining. Nonetheless, the
multiple logistic regression model was applied to assess
parameters independently associated with SCCA. The
ROC curve was drawn and the C parameter used to quan-
tify the predictive ability of the final regression model.
Up to 40% of all HCC’s do not produce AFP [5]. In
our study, 70.7% of the specimens did not stain for AFP.
No significant correlation was detected between the
serum level of AFP, AFP staining and SCCA staining.
Our study results support an invasive diagnostic
approach for a suspected malignant hepatic lesion since
the SCCA expression in the lesion might provide impor-
tant information regarding patient prognosis. We feel
that if only imaging studies are performed in cirrhotic
patients with a suspicious hepatic lesion, valuable prog-
nostic information might be missed.
Conclusions
SCCA is overexpressed in HCC. SCCA expression is
associated with tumor differentiation, cell proliferation
and apoptosis. Our study results confirm a potential
association of negative SCCA expression with other
markers of poor outcome in HCC.
More studies are needed to clarify the role of this
molecule and to further expand knowledge of the SCCA
antigen in HCC patients.
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